Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges by Piñero, Federico et al.
Hepatocellular carcinoma in Latin America: Diagnosis and 
treatment challenges
Federico Piñero, Jaime Poniachik, Ezequiel Ridruejo, Marcelo Silva
Federico Piñero, Ezequiel Ridruejo, Marcelo Silva, Liver Unit, 
Hospital Universitario Austral, Facultad de Ciencias Biomédicas, 
Universidad Austral, Pilar, Buenos Aires B1629HJ, Argentina
Federico Piñero, Ezequiel Ridruejo, Marcelo Silva, Latin 
American Liver Research Educational and Awareness Network, 
Buenos Aires B1629HJ, Argentina
Jaime Poniachik, Department of Gastroenterology and 
Hepatology, Hospital Clínico Universidad de Chile, Santiago de 
Chile, Región Metropolitana Santiago 46010, Chile
Jaime Poniachik, Gastroenterology and Hepatology, Clínica 
Santa María, Santiago de Chile, Región Metropolitana Santiago 
834-0518, Chile
Ezequiel Ridruejo, Hepatology Section, Centro de Educación 
Médica e Investigaciones Clínicas Norberto Quirno, Ciudad de 
Buenos Aires C1425ASG, Argentina
ORCID number: Federico Piñero (0000-0002-9528-2279); 
Jaime Poniachik (0000-0001-7958-3357); Ezequiel Ridruejo 
(0000-0002-3321-0683); Marcelo Silva (0000-0002-2287-7351).
Author contributions: Piñero F and Poniachik J contributed 
to concept and writing of the article; Ridruejo E and Silva M 
contributed to critical review and final approval of the article.
Conflict-of-interest statement: The authors of this manuscript 
have no conflicts of interest to declare. 
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript 
Correspondence to: Federico Piñero, MD, MSCE, Academic 
Research, Doctor, Hepatology and Liver Transplant Unit, 
Hospital Universitario Austral, Av. Presidente Perón 1500, Pilar, 
Buenos Aires B1629HJ, Argentina. fpinerof@cas.austral.edu.ar
Telephone: +54-230-4482000 
Fax: +54-230-4482236
Received: July 5, 2018 
Peer-review started: July 5, 2018
First decision: August 1, 2018
Revised: August 2, 2018 
Accepted: August 24, 2018 
Article in press: August 24, 2018
Published online: September 28, 2018
Abstract
Latin America, a region with a population greater than 
600000000 individuals, is well known due to its wide 
geographic, socio-cultural and economic heterogeneity. 
Access to health care remains as the main barrier 
that challenges routine screening, early diagnosis 
and proper treatment of hepatocellular carcinoma 
(HCC). Therefore, identification of population at risk, 
implementation of surveillance programs and access 
to curative treatments has been poorly obtained in 
the region. Different retrospective cohort studies from 
the region have shown flaws in the implementation 
process of routine surveillance and early HCC diagnosis. 
Furthermore, adherence to clinical practice guidelines 
recommendations assessed in two studies from Brazil 
and Argentina demonstrated that there is also room 
for improvement in this field, similarly than the one 
observed in Europe and the United States. In summary, 
Latin America shares difficulties in HCC decision-
making processes similar to those from developed 
countries. However, a transversal limitation in the 
region is the poor access to health care with the 
consequent limitation to standard treatments for overall 
population. Specifically, universal health care access 
to the different World Health Organization (WHO) 
levels is crucial, including improvement in research, 
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education and continuous medical training in order to 
expand knowledge and generation of data promoting a 
continuous improvement in the care of HCC patients.
Key words: Latin America; Liver cancer; Limitations; 
Challenge
© The Author(s) 2018. Published by Baishideng Publishing 
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Core tip: Which are the implications in regard to clinical 
decision making processes related to hepatocellular 
carcinoma (HCC) in daily practice in Latin America? 
Should we consider making these decisions taking into 
account both, local experiences and their feasibility 
together with the best available evidence in parallel 
with patient preferences? These decision-making 
processes must be individualized according to local 
barriers to health care systems. Primary prevention 
programs of liver diseases, surveillance for HCC and 
intervention programs following the best evidence will 
be possible only if we are aware of local barriers and 
develop efficient strategies to overcome them. 
Piñero F, Poniachik J, Ridruejo E, Silva M. Hepatocellular 
carcinoma in Latin America: Diagnosis and treatment challenges. 




Latin American comprises a region of the Americas 
of Latin origin, in which the most common speaking 
languages are Spanish and Portuguese. The region 
accounts for more than twenty million square kilometers 
of surface area, with more than six hundred million 
population. Due to its geographic extension, Latin 
America has a great socio-cultural heterogeneity and an 
important socio-economic difference among countries. 
While there are high earners like Chile and Uruguay 
with a Gross Domestic Product (GDP) per capita over $ 
20000, others like Haiti and Honduras have GDPs per 
capita lower than $ 5000[1]. At the same time, each 
country in itself is highly unequal, presenting some of the 
highest Globalization of Inequality (GINI) scores in the 
world. Brazil, Chile, Ecuador and Colombia all present 
GINIs above 0.45 for the year 2016; Argentina and 
Uruguay having slightly better scores[1]. In comparison, 
Sweden, Norway, Netherlands and Denmark all have 
GINI scores less than 0.30[1].
It is in this socio-cultural and economic scenario, 
where settles a large variety in access to health care 
systems in the region. These systems are mainly made 
up of a common payer and provider that is the state. 
However, in several countries, there are other type of 
health providers through social security and private 
insurances and providers. Furthermore, expenditure on 
access care in many Latin American countries comes 
from out-of-pocket money among high to middle 
income people. On the other hand, among low socio-
economic classes, expenditure comes purely and 
exclusively from public services, which in most of the 
cases provide with low to regular quality of medical care 
services and shortage of appropriate medical supplies 
and devices. 
WHERE DO WE STAND IN 
LATIN AMERICA REGARDING 
HEPATOCELLULAR CARCINOMA?
Hepatocellular carcinoma (HCC) is the second leading 
cause of cancer related death worldwide and the main 
cause of cancer in patients with cirrhosis. Incidence of 
hepatocellular carcinoma varies according to geographic 
location, depending on the prevalence of viral hepatitis 
among the world. The predominant reported causes 
of HCC in different geographic areas around the world 
have been related with chronic hepatitis C virus (HCV) 
or hepatitis B virus (HBV) infection and alcoholic liver 
disease[2-5]. Heterogeneous data regarding epidemiology 
of HCC in Latin America has been reported[6-12]. While 
HCV and alcoholic liver disease are the most frequent 
etiologies of HCC in the region, HBV is a leading cause 
in some countries, mainly in Brazil. More recently, we 
have observed a changing epidemiological trend of HCC 
towards an increasing non-alcoholic fatty liver disease, 
becoming an important public health burden in the 
region[6,7].
As previously proposed by the World Health 
Organization (WHO) the structural challenge in the region 
is the uneven access to health care. To our knowledge 
there is not even one country with an integrated program 
to assist on the prevention of chronic liver diseases 
and early identification of the population at risk for 
developing HCC. Consequently, the common challenge 
for scientific societies is to induce regional policy 
makers to develop interventions and strategies able to 
identify the population at risk, implement surveillance 
programs, and improve access to curative and palliative 
treatments. Once we have assured access to adequate 
care we should move into next step which is the correct 
adherence to recommendations from clinical practice 
guidelines[2-5].
A clinical case scenario as an example of where do we 
fail in Latin America
The following clinical case demonstrates the regional 
shortcomings related to HCC diagnosis at late stages and 
its therapeutic consequences. A 60-year-old male patient 
with compensated cirrhosis and clinically significant portal 
hypertension due to chronic HCV infection, who started 
antiviral treatment with direct-acting antiviral agents, 
began an erratic path of ultrasound (US) screening for 
2 September 28, 208|Volume 24|Issue 36|WJG|www.wjgnet.com
Piñero F et al . Challenges of HCC in Latin America
HCC. Surveillance was performed by non-liver expert 
sonographers due to insurance’s related lack of access to 
academic sites. Initially a 24-mm nodule was visualized 
and he was recommended to stay on a follow-up visit 
with no further imaging evaluation. Twelve months 
later, another US was performed; this time the nodule 
grew to 38 mm. He performed an abdominal computed 
tomography (CT) scan with oral contrast only, and the 
finding of an “uncharacteristic” nodule leaded to a CT-
guided biopsy. The pathologic report was “nodules of 
hepatocellular regeneration separated by broad fibrous 
septa, cirrhosis”. Result: no cancer. His physician 
suggested him to continue life normally and the patient 
happily went home.
A year later, a liver specialist suggested him to 
perform an abdominal CT scan with intravenous contrast. 
A heterogeneous 80-mm diameter lesion in the right 
hepatic lobe with “non-characteristic findings” was 
observed. Not satisfied, the patient looked for a second 
opinion. A second hepatologist performed a three-
phase dynamic abdominal magnetic resonance imaging 
(MRI). Result: one lesion with arterial enhancement and 
wash out during portal and late phases: HCC of 83 mm, 
without vascular invasion. Serum alpha-fetoprotein value 
was 1200 ng/mL. 
In the end, the patient consulted at least 4 medical 
doctors during a 2-year period, with extended and 
inadmissible delay in HCC diagnosis that at this point 
will probably exclude him from potentially curative 
treatments. Where did we fail?
Early diagnosis of HCC: Challenges and areas of 
improvement
This case, clearly illustrates some of the reasons for 
failure in routine surveillance and HCC diagnosis at early 
stages in Latin America, and as a consequence, failure 
in the appropriate staging and selection of therapies. 
Screening failure entails three important points to be 
considered. First, absence of early identification of the 
population at risk, such as chronic HBV or HCV. Second, 
ineffective application of routine surveillance (semi-annual 
ultrasound performed by expert operators) and third, 
errors in interpretation of a positive or negative screening 
tests, misinterpreting its sensitivity and specificity.
Surveillance for HCC in Latin America demands 
a continuous improvement. Different retrospective 
cohort studies have shown flaws in the implementation 
process of routine surveillance, the consequent failure 
in the diagnosis in early stages and finally a notorious 
negative impact upon patient survival[8-12] (Table 1).
Overall, surveillance programs reported to be applied 
in less than 50% of the patients in Latin America. This 
number perhaps does not show the “real” regional 
situation, since most of this data came from academic 
rather than general hospitals. Consequently, screening 
failure for HCC in this region might be even greater, 
demanding strategies to improve its implementation 
such as application of US done by experts, correct 
interpretation of imaging tests and finally, adequacy of 
therapeutic decisions according to the best evidence-
based-medicine. Consequently, early HCC diagnosis 
should be the aim of these strategies.
As exemplified in the clinical case, the misuse of 
diagnostic tools delays the correct diagnosis. HCC 
diagnosis implies an appropriate oncologic imaging 
paradigm, not requiring histological confirmation for 
diagnosis in most of the cases. However, discordance 
between images and histology may occur. This situation 
has been reported up to 10% in Argentina when 
comparing imaging reports and explanted liver data 
from liver transplanted patients[13,14]. In a multicenter 
Latin American cohort study, false positives cases were 
less than 3%[15]. Two different situations need to be 
further clarified when discussing imaging accuracy 
against histological confirmation of HCC. On one 
hand, when false positives are considered, it should be 
important to address if complete necrotic nodules were 
included as false positive cases resulting in a biased 
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Table 1  Surveillance for hepatocellular carcinoma in Latin America
Study Population Design Results
Fassio et al[8] n = 240 HCC Brazil, Arg, Colombia, 
Chile, Uruguay, Venezuela
Prospective cohort (Surveillance 
retrospectively analyzed)
54% under surveillance BCLC A 70% vs 
39% not under surveillance No survival 
analysis
Paranaguá-Vezozzo et al[9] n = 884 Cirrhosis Child A-B Brazil, 
Sao Paulo
Retrospective cohort US +/- AFP 
annual
HCC annual incidence 2.9% 75% under 
annual surveillance 80% within Milan, 
better survival
Piñero et al[0] n = 643 Cirrhosis, waiting list for 
liver transplantation. Argentina
Retrospective cohort Surveillance 
Failure = incidental HCC in the 
explant
US accuracy: S 33% y E 99%
Campos Appel-da-Silva et al[] n = 453 Child A-C Cirrhosis Brazil, 
Porto Alegre
Retrospective cohort US +/- AFP 
every 6 mo
50.7% under surveillance More BCLC 
0-A vs no screening Better survival 
within Milan criteria
Debes et al[2] n = 336 HCC Brazil, Argentina, 
Colombia, Peru, Uruguay, Ecuador
Retrospective cohort 47% under surveillance Better survival 
vs symptomatic diagnosis (adjusted for 
lead-time bias)
BCLC: Barcelona Clinic Liver Cancer; HCC: Hepatocellular carcinoma; US: Ultrasound.
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including those from Asia (APASL)[5], Japan and South 
Korea. Consequently, there is a wide range of treatment 
algorithms when considering HCC.
The BRIDGE study demonstrated the great 
heterogeneity in terms of the treatments performed 
worldwide at each stage and far from that recommended 
in the ideal situation[19]. Global and individual context 
makes therapeutic decisions in HCC heterogeneous 
in real life. Adherence to clinical practice guidelines 
recommendations varies between 40%-70% in different 
retrospective cohort studies[20-26]. Two Latin American 
studies evaluated adherence to BCLC and its impact on 
survival. In a study from Brazil, adherence to BCLC did 
not have a favorable impact on survival[25]. However, 
there was a selection bias when “non-adherence” was 
categorized in those patients within BCLC-D stage who 
were candidates for liver transplantation. Precisely, the 
BCLC clarifies in its footnote that these patients must 
be transplanted. In a dual cohort study in Argentina, 
adherence to BCLC was greater than 50%, being 
associated with better overall survival[26] (Table 2).
In summary, although Latin America shares some 
difficulties in HCC decision-making processes similar 
to those reported in some developed countries, we still 
have big gaps when compared to them. These gaps are 
seen in medical education, on early and accurate HCC 
diagnosis, and in universal access to good diagnostic 
technology and to curative treatments. Until they are 
corrected, discrepancy on HCC related survival would 
remain present.
report. On the other hand, discrepancy between images 
and explanted liver should be considered taking into 
account potential tumor progression, and locoregional 
response to treatments during the waiting list period.
Nevertheless this led to changes in diagnostic criteria 
for HCC in patients enrolled for liver transplantation 
in Argentina aimed to improve imaging diagnostic 
accuracy. Although the idea was novel, LIRADS criteria 
implementation leaded even to a greater uncertainty for 
those cases where HCC diagnosis is probable or possible 
(LIRADS 3 or 4). Moreover, imaging expert’s agreement 
on LIRADS in the daily practice has been not assessed 
at all. Thus, LIRADS system seemed to make the clinical 
decision making process even more complex in daily 
practice in that country[16,17].
Challenges regarding staging and adherence to 
recommended treatment options from clinical practice 
guidelines
HCC staging considering the Barcelona Clinic Liver 
Cancer (BCLC) algorithm has been recommended in 
different clinical practice guidelines[3,4], including that 
from the Latin American Association for the Study of 
the Liver (ALEH)[3]. However, strict adherence to these 
therapeutic recommendations is often not feasible in daily 
practice. This does not contradict the BCLC algorithm, 
since its explicitly recommends that the therapeutic 
choice must be individualized considering feasibility, 
access and preferences of the patients[18]. In addition, 
there are different guidelines and recommendations, 
Table 2  Adherence to clinical practice guidelines around the world and in Latin America
Study Population Design Results
Leoni et al[20] n = 227 HCV 58% Child A 54% Retrospective cohort (2005-200) One 
center
At HCC diagnosis: BCLC 0-A 55% Adherence to 
BCLC 60% Higher adherence among BCLC A 86%
Gashin et al[2] n = 37 HCV 62% Retrospective cohort (2009-200) One 
center
Adherence to BCLC 62% Better overall survival 
Heterogeneous causes of non-adherence
Kim et al[22] n = 355 HBV 77% Child A 82% Retrospective cohort (2005-2009) One 
center
At HCC diagnosis: BCLC A 59% Adherence to BCLC 
49% Better survival for adherence, except BCLC-D 
(BCLC D who were transplanted were considered 
“non-adherence”)
Wallace et al[23] n = 292 OH-HCV 65% Retrospective cohort (2006-204) One 
center
At HCC diagnosis: BCLC 0-A 64% Adherence to 
BCLC 48% vs HKLC 56% (P.00) No better survival 
among BCLC adherence vs no-adherence but better 
survival among HKLC (TACE before transplant was 
considered “no-adherence”)
Guarino et al[24] n = 008 HCV Child A 73% Retrospective cohort (203-205) 
Multicenter study
At HCC diagnosis: BCLC 0-A 59% Adherence BCLC 
7%, lower in BCLC B 36% and C 46% No better 
survival (TACE before transplant was considered 
“no-adherence”)
Kikuchi et al[25] n = 364 HBV 53% Child A 53% Retrospective cohort (200-202) One 
center
At HCC diagnosis: BCLC A 36% Adherence BCLC 
52% Lower adherence in BCLC C-D No better 
survival, except in BCLC A (BCLC D who were 
transplanted were considered “non-adherence”)
Piñero et al[26] n = 708 HCV 58% Child A 54% Dual cohort (2009-206) Multicenter 
study
At HCC diagnosis: BCLC 0-A 47% Adherence BCLC 
53% initial, 63% subsequently Adherence to BCLC: 
better survival HR 0.67 (CI: 0.52-0.87)
BCLC: Barcelona Clinic Liver Cancer; HKLC: Hong Kong Liver Cancer algorithm; HCV: Hepatitis C virus; HBV: Hepatitis B virus; TACE: Transarterial 
chemoembolization.
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PERSPECTIVE
Consequently, we shall make decisions considering 
local education, expertise and feasibility together with 
the best available evidence. Ultimately, this decision-
making-process must be individualized[27].
Which are the areas for improvement in Latin 
America? Specifically, universal health care access as 
per World Health Organization (WHO) recommendation 
is crucial. This includes improvement in transmission 
of information and medical education from academic 
to primary health care centers, focusing on prevention 
of development of liver diseases, identification of 
population at risk for HCC, systematic implementation 
of routine surveillance programs, improvement in the 
diagnostic work-up process and finally, promoting 
overall access to all treatments strategies which have 
shown improvement in patient´s survival (Figure 1). 
Finally, an important field to promote in the region is 
the development of research consortia such as the Latin 
American Liver Research Educational and Awareness 
Network (LALREAN), through which we can multiply 
medical education and generation of regional data 
necessary to develop efficient health interventions for 
improvement the care of patients with HCC[28].
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